Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Ramkrishna Makani"'
Autor:
Zeeshan Mansuri, Ramkrishna Makani, Chintan Trivedi, Mahwish Adnan, Ramu Vadukapuram, John Rafael, Ashutosh Lodhi, Abhishek Reddy
Publikováno v:
Frontiers in Psychiatry, Vol 13 (2022)
IntroductionSecond-generation antipsychotics are associated with significant weight gain. The aim of this systematic review and meta-analysis was to determine the efficacy and safety of metformin for the treatment of weight gain in children and young
Externí odkaz:
https://doaj.org/article/12fd0c782fba4860887013078a544303
Publikováno v:
Depression Research and Treatment, Vol 2015 (2015)
Depression affects about 121 million people worldwide and prevalence of major depressive disorder (MDD) in US adults is 6.4%. Treatment resistant depression (TRD) accounts for approximately 12–20% of all depression patients and costs $29–$48 bill
Externí odkaz:
https://doaj.org/article/7ad887e430a148128c6d33608cc042d6
Autor:
Zeeshan, Mansuri, Krupa, Patel, Bhumika, Shah, Chintan, Trivedi, Mahwish, Adnan, Ramu, Vadukapuram, Muhammad Khalid, Zafar, Ramkrishna, Makani, Abhishek, Reddy
Publikováno v:
Journal of Nervous & Mental Disease. 210:880-882
Publikováno v:
Journal of Psychiatric Practice. 28:3-13
Growing data on suicidal behavior among members of the lesbian, gay, bisexual, transgender, queer, questioning, and other sexual/gender minority (LGBTQ+) communities, particularly in the transgender subgroup, demonstrate that there is a stark elevati
Autor:
Miles M Nakaska, Keerthika Mathialagan, Sayeda A Basith, Ramkrishna Makani, Aabha Shakya, Albulena Sejdiu, Vaishalee Namdev, Siddharth Gupta
Publikováno v:
Cureus
Objectives To determine the demographic predictors of suicidal behaviors and measure the association between the spectrum of substance use disorders (SUD) and hospitalization for suicidal behaviors in the adolescent population. Methods We conducted a
Publikováno v:
Journal of the American Academy of Child & Adolescent Psychiatry. 60:S214-S215
Publikováno v:
Cureus
Quetiapine is a second-generation antipsychotic (SGA) approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia, mania, and aggression in children and adolescents. It is also commonly used as an off-label medication to tre
Publikováno v:
Journal of the American Academy of Child & Adolescent Psychiatry. 60:S239
Autor:
Zeeshan Mansuri, Ramkrishna Makani, Chintan G. Trivedi, Mahwish Adnan, Zainab Gandhi, Taranjeet S. Jolly
Publikováno v:
Journal of the American Academy of Child & Adolescent Psychiatry. 59:S215-S216
Autor:
Tapan Parikh, Ramkrishna Makani
Publikováno v:
American Journal of Psychiatry Residents' Journal. 12:4-6